Payment overview · 2025
General Payments
$729.91
57 reported records · 10 companies
Healthcare provider profile · identity verified
James Louthan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KINGSPORT, TN · NPI 1477556157
Verified facts
What the public records show
CMS Open Payments records show James Louthan, MD received $729.91 in general payments during 2025 across 57 reported records.
ABBVIE INC. accounted for 32.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $234.83 | 32.2% | 29 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $188.01 | 25.8% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $112.01 | 15.3% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $61.18 | 8.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $52.16 | 7.2% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.09 | 3.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $15.61 | 2.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.89 | 2.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.61 | 1.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.52 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $684.91 | 56 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $148.50 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $143.13 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $137.43 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $91.70 | 17 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $90.76 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $67.01 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $61.18 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.27 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $36.94 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.90 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 155 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 105 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
69 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
155 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
105 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 660 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 632 | 163 |
| Losartan Potassium | Losartan Potassium | 625 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 614 | 162 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 568 | 162 |
| Oxycodone Hcl | Oxycodone Hcl | 495 | 55 |
| Lisinopril | Lisinopril | 488 | 124 |
| Gabapentin | Gabapentin | 469 | 74 |
| Omeprazole | Omeprazole | 424 | 122 |
| Hydrochlorothiazide | Hydrochlorothiazide | 395 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 376 | 111 |
| Alprazolam | Alprazolam | 353 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 338 | 91 |
| Tamsulosin Hcl | Tamsulosin Hcl | 326 | 88 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 323 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 295 | 78 |
| Fluticasone Propionate | Fluticasone Propionate | 275 | 92 |
| Eliquis | Apixaban | 263 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 250 | 44 |
| Meloxicam | Meloxicam | 243 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 239 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 225 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 220 | 57 |
| Simvastatin | Simvastatin | 219 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 211 | 71 |
| Clonazepam | Clonazepam | 210 | 28 |
| Atenolol | Atenolol | 200 | 59 |
| Montelukast Sodium | Montelukast Sodium | 200 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 197 | 41 |
| Metformin Hcl | Metformin Hcl | 189 | 55 |
| Tizanidine Hcl | Tizanidine Hcl | 179 | 41 |
| Allopurinol | Allopurinol | 175 | 46 |
| Metformin Hcl Er | Metformin Hcl | 175 | 42 |
| Furosemide | Furosemide | 167 | 56 |
| Tramadol Hcl | Tramadol Hcl | 167 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 159 | 41 |
| Mounjaro | Tirzepatide | 155 | 22 |
| Alendronate Sodium | Alendronate Sodium | 153 | 40 |
| Pregabalin | Pregabalin | 149 | 27 |
| Morphine Sulfate Er | Morphine Sulfate | 148 | 19 |
| Ibuprofen | Ibuprofen | 147 | 35 |
| Diazepam | Diazepam | 145 | 19 |
| Famotidine | Famotidine | 143 | 38 |
| Trazodone Hcl | Trazodone Hcl | 142 | 31 |
| Carvedilol | Carvedilol | 141 | 35 |
| Aripiprazole | Aripiprazole | 139 | 29 |
| Prednisone | Prednisone | 139 | 80 |
| Potassium Chloride | Potassium Chloride | 138 | 42 |
| Jardiance | Empagliflozin | 134 | 27 |
| Glimepiride | Glimepiride | 132 | 33 |
| Torsemide | Torsemide | 129 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 118 | 26 |
| Benazepril Hcl | Benazepril Hcl | 116 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 116 | 29 |
| Lorazepam | Lorazepam | 114 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 109 | 27 |
| Celecoxib | Celecoxib | 106 | 25 |
| Ozempic | Semaglutide | 105 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 103 | 29 |
| Sertraline Hcl | Sertraline Hcl | 103 | 29 |
| Promethazine Hcl | Promethazine Hcl | 102 | 20 |
| Farxiga | Dapagliflozin Propanediol | 100 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 99 | 23 |
| Chlorthalidone | Chlorthalidone | 98 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 89 | 21 |
| Irbesartan | Irbesartan | 88 | 20 |
| Temazepam | Temazepam | 88 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 87 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 87 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 22 |
| Ondansetron Odt | Ondansetron | 83 | 30 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 81 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 75 | 23 |
| Amoxicillin | Amoxicillin | 73 | 53 |
| Cefdinir | Cefdinir | 73 | 50 |
| Fluconazole | Fluconazole | 72 | 46 |
| Valacyclovir | Valacyclovir Hcl | 71 | 22 |
| Xarelto | Rivaroxaban | 71 | 15 |
| Linzess | Linaclotide | 69 | 14 |
| Clonidine Hcl | Clonidine Hcl | 67 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 63 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 38 |
| Meclizine Hcl | Meclizine Hcl | 59 | 24 |
| Testosterone Cypionate | Testosterone Cypionate | 59 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 58 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | 18 |
| Spironolactone | Spironolactone | 55 | 17 |
| Estradiol | Estradiol | 52 | 14 |
| Bupropion Xl | Bupropion Hcl | 51 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 14 |
| Azithromycin | Azithromycin | 50 | 37 |
| Buspirone Hcl | Buspirone Hcl | 48 | 15 |
| Mirtazapine | Mirtazapine | 48 | 12 |
| Baclofen | Baclofen | 46 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 46 | 15 |
| Synthroid | Levothyroxine Sodium | 46 | 11 |
| Carisoprodol | Carisoprodol | 45 | suppressed |
| Finasteride | Finasteride | 45 | 15 |
| Fosinopril Sodium | Fosinopril Sodium | 45 | suppressed |
| Levetiracetam | Levetiracetam | 44 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 32 |
| Lovastatin | Lovastatin | 43 | 13 |
| Nifedipine Er | Nifedipine | 43 | 12 |
| Ibu | Ibuprofen | 40 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 40 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 12 |
| Methylphenidate Hcl | Methylphenidate Hcl | 39 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Methotrexate | Methotrexate Sodium | 35 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 35 | 32 |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 34 | suppressed |
| Nystatin | Nystatin | 34 | 16 |
| Warfarin Sodium | Warfarin Sodium | 34 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Phenobarbital | Phenobarbital | 31 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 31 | 11 |
| Topiramate | Topiramate | 31 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Spiriva Respimat | Tiotropium Bromide | 30 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 28 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 18 |
| Sucralfate | Sucralfate | 26 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Digoxin | Digoxin | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Belsomra | Suvorexant | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 16 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Glyburide | Glyburide | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Telmisartan | Telmisartan | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Dexamethasone | Dexamethasone | 15 | 13 |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Zolmitriptan | Zolmitriptan | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $729.91 · 57 records | ABBVIE INC. | AREXVY, Auvelity, BREZTRI, BodyGuardian, KRYSTEXXA, MOUNJARO, Ozempic, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error